QUEBEC CITY, March 22 /PRNewswire/ -- Infectio Diagnostic Inc. (IDI) has just received clearance from the US Food and Drug Administration (FDA) to market its new ultra-rapid test (IDI-MRSA(TM)) for detecting methicillin- resistant Staphylococcus aureus (MRSA). This is the first MRSA test cleared by the USFDA for use directly on clinical specimens. This is the second IDI test cleared by the FDA.
IDI-MRSA(TM) is also the only test licensed by Health Canada for the detection of MRSA directly from clinical specimens. The license was received in November 2003.
MRSA is one of the main causes of nosocomial infections which are responsible for the death of thousands of hospitalized patients every year. Today, healthcare institutions are spending huge amount of money to fight and prevent the spread of these infections. The ultra-rapid identification of MRSA will significantly reduce such costs. With IDI-MRSA(TM), an answer is obtained within one hour, whereas the traditional method takes 2 to 5 days.
The President of IDI, Jean-Pierre Gayral, states "We have accomplished a worldwide breakthrough. Our test is the first and only one that allows for the immediate detection of MRSA. It provides the medical community with an essential tool for the prevention and control of these infections. This milestone confirms our position at the leading edge of technology in diagnostic products."
IDI recently signed a partnership agreement with Chiron Corporation of Emeryville, California, for the detection of microbial contaminants in platelet units. IDI also just granted a license to bioMerieux, a worldwide leader in clinical microbiology.
IDI is a private biotechnology company specialized in the development of molecular diagnostic tests for bacterial, fungal and parasitic infections. The company's head office is located in Quebec City (Canada).
INFECTIO DIAGNOSTIC INC.
CONTACT: Diane Periard, Assistant to the President and CEO, (418)681-4343, extension 229